mifepristone has been researched along with Diabetes Mellitus, Type 2 in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Apelqvist, T; Barkhem, T; Färnegårdh, M; Fung, S; Goos-Nilsson, A; Grynfarb, M; Hagberg, L; Höglund, M; Hutchins, C; Jacobson, PB; Jae, HS; Jakob, C; Kauppi, B; Koehler, K; Kym, PR; Lai, C; Link, JT; Nguyen, P; Ohman, L; Osterlund, M; Rhonnstad, P; Sandberg, J; Tu, N; von Geldern, TW; Wang, J; Wilcox, D | 1 |
| Allan, G; Demarest, K; Fiordeliso, JJ; Gunnet, J; Jiang, W; Linton, O; Lundeen, S; Sui, Z; Tannenbaum, P; Xu, J; Zhu, P | 1 |
| Athimulam, S; Bancos, I; Delivanis, DA | 1 |
| Braunstein, GD; Feldman, D; Gross, C; Katznelson, L; Loriaux, DL; Schteingart, DE | 1 |
| Andrew, R; Bastin, ME; Gray, CD; Iredale, JP; Macfarlane, DP; Marshall, I; Preston, T; Raubenheimer, PJ; Walker, BR | 1 |
| Flatt, PR; Frizzell, N; Gault, VA; McKillop, AM; Taylor, AI | 1 |
| Biller, BM; Findling, JW; Fleseriu, M; Gross, C; Molitch, ME; Schteingart, DE | 1 |
| Friedman, TC; Liu, Y; Lutfy, K; Nakagawa, Y; Sakurai, R; Tripathi, PV; Wang, Y | 1 |
| Clifton, LG; Lin, P; McNulty, JA; Pahel, GL; Shen, Y; Stimpson, SA; Trump, RP; Yang, B | 1 |
| Alam, T; Chen, L; McCorkle, K; McGarry, JD; Ogawa, A; Ohneda, M; Pieber, TR; Stein, DT; Unger, RH | 1 |
| Inman, LR; Johnson, JH; Ohneda, M; Unger, RH | 1 |
| Farrell, CJ; Friedman, JE; Hakimi, P; Herron, LM; Ishizuka, T; Lechner, P; McCormack, SE; Sun, Y; Yun, JS | 1 |
3 trial(s) available for mifepristone and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Global clinical response in Cushing's syndrome patients treated with mifepristone.
Topics: Adult; Aged; Blood Pressure; Cushing Syndrome; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Hormone Antagonists; Humans; Hypertension; Male; Middle Aged; Mifepristone; Quality of Life; Receptors, Glucocorticoid | 2014 |
Effects of acute glucocorticoid blockade on metabolic dysfunction in patients with Type 2 diabetes with and without fatty liver.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Metabolism; Enzyme Inhibitors; Fatty Acids, Nonesterified; Glycerol; Hormone Antagonists; Humans; Hydrocortisone; Indicator Dilution Techniques; Insulin; Liver; Magnetic Resonance Spectroscopy; Male; Metyrapone; Middle Aged; Mifepristone; Non-alcoholic Fatty Liver Disease; Receptors, Glucocorticoid; Scotland; Steroid 11-beta-Hydroxylase; Time Factors; Treatment Outcome | 2014 |
Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Composition; Body Weight; Cushing Syndrome; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Hormone Antagonists; Humans; Hydrocortisone; Hypertension; Male; Middle Aged; Mifepristone; Quality of Life; Quinolines; Receptors, Glucocorticoid; Urea | 2012 |
10 other study(ies) available for mifepristone and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes.
Topics: Animals; Bile Acids and Salts; Binding Sites; Bridged-Ring Compounds; Cells, Cultured; CHO Cells; Computer Simulation; Cricetinae; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Hypothalamo-Hypophyseal System; Liver; Male; Mice; Models, Molecular; Pituitary-Adrenal System; Rats; Rats, Sprague-Dawley; Receptors, Glucocorticoid; Structure-Activity Relationship | 2004 |
Discovery of novel phosphorus-containing steroids as selective glucocorticoid receptor antagonist.
Topics: Animals; Biological Availability; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Humans; Inhibitory Concentration 50; Mifepristone; Phosphorus; Rats; Receptors, Glucocorticoid; Steroids; Structure-Activity Relationship | 2007 |
Modern Management of Mild Autonomous Cortisol Secretion.
Topics: 14-alpha Demethylase Inhibitors; Adrenal Cortex Neoplasms; Adrenal Insufficiency; Adrenalectomy; Adrenocortical Adenoma; Adrenocorticotropic Hormone; Dehydroepiandrosterone Sulfate; Diabetes Mellitus, Type 2; Disease Management; Dyslipidemias; Enzyme Inhibitors; Glucocorticoids; Hormone Antagonists; Humans; Hydrocortisone; Hypertension; Incidental Findings; Ketoconazole; Metyrapone; Mifepristone; Mortality; Obesity; Osteoporosis; Postoperative Hemorrhage; Risk; Saliva; Severity of Illness Index | 2019 |
Effect of RU486 on hepatic and adipocyte gene expression improves diabetes control in obesity-type 2 diabetes.
Topics: Adipocytes; Adipose Tissue, White; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedule; Epididymis; Fasting; Feeding Behavior; Gene Expression Regulation; Glucose Tolerance Test; Insulin; Liver; Male; Mice; Mice, Obese; Mifepristone; Obesity; Pancreas; RNA, Messenger; Triglycerides | 2009 |
FDA puts restrictions on use of controversial diabetes drug.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug and Narcotic Control; Drug Approval; Drug Industry; Drug Prescriptions; Humans; Hypoglycemic Agents; Mifepristone; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2011 |
Increased glucocorticoid receptor and 11{beta}-hydroxysteroid dehydrogenase type 1 expression in hepatocytes may contribute to the phenotype of type 2 diabetes in db/db mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Gene Expression Regulation; Glucose; Hepatocytes; Male; Mice; Mice, Obese; Mifepristone; Phenotype; Receptors, Glucocorticoid; RNA, Messenger; Transcription, Genetic | 2005 |
RU486 did not exacerbate cytokine release in mice challenged with LPS nor in db/db mice.
Topics: Adrenocorticotropic Hormone; Animals; Blood Glucose; Chemokine CCL2; Corticosterone; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation, Enzymologic; Glucose-6-Phosphatase; Hormone Antagonists; Hypoglycemic Agents; Interleukin-6; Lipopolysaccharides; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Mifepristone; Obesity; Protein Serine-Threonine Kinases; Receptors, Glucocorticoid; Receptors, Leptin; Tumor Necrosis Factor-alpha | 2008 |
Amylin-insulin relationships in insulin resistance with and without diabetic hyperglycemia.
Topics: Amyloid; Animals; Dexamethasone; Diabetes Mellitus, Type 2; Hyperglycemia; Insulin; Insulin Resistance; Insulin Secretion; Islet Amyloid Polypeptide; Male; Mifepristone; Obesity; Pancreas; Rats; Rats, Wistar; Rats, Zucker; Receptors, Glucocorticoid; RNA, Messenger; Somatostatin | 1993 |
GLUT-2 function in glucose-unresponsive beta cells of dexamethasone-induced diabetes in rats.
Topics: 3-O-Methylglucose; Animals; Arginine; Biological Transport; Blood Glucose; Dexamethasone; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Transporter Type 2; In Vitro Techniques; Insulin; Insulin Secretion; Islets of Langerhans; Methylglucosides; Mifepristone; Monosaccharide Transport Proteins; Rats; Rats, Zucker | 1993 |
Phosphoenolpyruvate carboxykinase (GTP) gene transcription and hyperglycemia are regulated by glucocorticoids in genetically obese db/db transgenic mice.
Topics: Animals; Binding Sites; Diabetes Mellitus, Type 2; DNA; Genes, Reporter; Glucocorticoids; Hormone Antagonists; Hyperglycemia; Insulin Receptor Substrate Proteins; Liver; Mice; Mice, Inbred C57BL; Mice, Obese; Mice, Transgenic; Mifepristone; Phosphatidylinositol 3-Kinases; Phosphoenolpyruvate Carboxykinase (GTP); Phosphoproteins; Promoter Regions, Genetic; Rats; Receptor, Insulin; Transcription, Genetic | 1997 |